Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 00:43:24 GMT 2023
by
admin
on
Sat Dec 16 00:43:24 GMT 2023
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
6K15ABL77G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
EVICEL (AUTHORIZED: HEMOSTASIS, REGULATORY)
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
RAPLIXA (AUTHORIZED: HEMOSTASIS, SURGICAL)
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
TACHOSIL (AUTHORIZED: HEMOSTASIS, SURGICAL)
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
||
|
NCI_THESAURUS |
C78311
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
||
|
NDF-RT |
N0000184169
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
825006
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB20551
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY | |||
|
100000092746
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY | |||
|
N0000009252
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY | Increased Coagulation Factor Activity [PE] | ||
|
C81121
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY | |||
|
DB11571
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY | |||
|
6K15ABL77G
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY | |||
|
N0000007914
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY | Blood Coagulation Factors [Chemical/Ingredient] | ||
|
9002-04-4
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY | |||
|
m10807
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
6K15ABL77G
Created by
admin on Sat Dec 16 00:43:25 GMT 2023 , Edited by admin on Sat Dec 16 00:43:25 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_28 | 1_44 |
1_119 | 2_9 |
1_173 | 1_187 |
1_201 | 1_231 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_53 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
SUB_CONCEPT->SUBSTANCE | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET |
Napsagatran [RO 466240], a reversible and highly selective thrombin inhibitor, was in development with Roche for use in myocardial infarction and thrombosis. Napsagatran efficiently inhibits and delays thrombin generation in human coagulating plasma. This reduced thrombin generation might be caused by inhibition of thrombin-mediated feedback reactions during blood coagulation. Ro 46-6240 inhibited clot-bound thrombin three times more potently than fluid-phase thrombin (IC50 19 vs 56 ng/ml) while hirudin was two times (IC50 8 vs 3 ng/ml) and heparin six times (IC50 1,205 vs 200 ng/ml) less active against clot-bound thrombin compared with fluid-phase thrombin.
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Argatroban is capable of inhibiting the action of both free and clot-associated thrombin.
Ki
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|